In the BioHarmony Drug Report Database

"Preview" Icon

Rivaroxaban

Xarelto (rivaroxaban) is a small molecule pharmaceutical. Rivaroxaban was first approved as Xarelto on 2008-09-30. It is used to treat pulmonary embolism and venous thrombosis in the USA. It has been approved in Europe to treat acute coronary syndrome, atrial fibrillation, coronary artery disease, peripheral arterial disease, and pulmonary embolism amongst others. The pharmaceutical is active against coagulation factor X. Xarelto’s patents are valid until 2039-01-31 (FDA).

 

Trade Name

 

Xarelto
 

Common Name

 

rivaroxaban
 

ChEMBL ID

 

CHEMBL198362
 

Indication

 

acute coronary syndrome, atrial fibrillation, coronary artery disease, peripheral arterial disease, pulmonary embolism, replacement arthroplasty, stroke, venous thromboembolism, venous thrombosis
 

Drug Class

 

Antithrombotic: blood coagulation factor XA inhibitors

Image (chem structure or protein)

Rivaroxaban structure rendering